Zoetis Inc. reports developments as a global animal health company serving veterinarians, livestock producers and pet owners. Its updates center on medicines, vaccines, diagnostics, biopharmaceuticals and digital solutions for companion animals and livestock, organized commercially through U.S. and International segments.
Recurring news includes quarterly results and guidance, dividend declarations, investor conference presentations, pipeline and product-regulatory updates, and portfolio activity tied to animal health innovation. Company materials also describe R&D work across areas such as chronic kidney disease, oncology, cardiology, anxiety and obesity, as well as approved long-acting osteoarthritis pain products Lenivia and Portela.
Zoetis reported strong Q1 2021 results with $1.9 billion in revenue, a 22% increase year-over-year. Net income rose 32% to $559 million, or $1.17 per diluted share. Adjusted net income was $603 million, up 33%. The company raised its full-year revenue guidance to $7.500-$7.625 billion, citing robust operational growth across its product segments, particularly in companion animal products, and successful sales in international markets. New product approvals and a recovering veterinary sector contributed to positive momentum. CEO Kristin Peck emphasized the company's diverse portfolio and commitment to innovation.
Zoetis (NYSE: ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on May 6, 2021, to discuss its first quarter 2021 financial results. CEO Kristin Peck and CFO Glenn David will present the financial outcomes and address questions from analysts. Investors can access the live event via the Zoetis investor website, with a replay available post-event. In 2020, Zoetis generated $6.7 billion in revenue, emphasizing its position as a leading animal health company.
Summary not available.
Zoetis (NYSE:ZTS) is set to participate in the Cowen 41st Annual Health Care Conference on March 1, 2021. CEO Kristin Peck will present at 1:20 p.m. ET and answer questions from analysts. Investors can access a live audio webcast of the presentation at investor.zoetis.com/events-presentations, with a replay available afterwards. As a leader in animal health, Zoetis generated $6.7 billion in revenue in 2020 and operates in over 100 countries, providing medicines, vaccines, and diagnostics for animal care.
Zoetis (NYSE:ZTS) will join the Bank of America Securities 2021 Animal Health Summit Virtual Forum on February 25, 2021. Glenn David, Executive Vice President and CFO, will present at 7:50 a.m. ET. Investors can listen to the live audio webcast at investor.zoetis.com/events-presentations, with a replay available post-event. Zoetis, a leader in animal health, reported $6.7 billion in annual revenue for 2020 and has a team of approximately 11,300 employees, providing essential products across over 100 countries.
Zoetis (NYSE:ZTS) has received marketing authorization from the European Commission for Solensia (frunevetmab), a groundbreaking treatment for feline osteoarthritis (OA). Affecting approximately 40% of cats, OA can severely impact their quality of life. Solensia is a monoclonal antibody that targets Nerve Growth Factor (NGF) to alleviate OA pain and is administered monthly by veterinarians. Clinical studies reveal that 76% of cat owners reported sustained improvements in their pets' pain symptoms, enhancing overall activity and sociability.
Zoetis Inc. (ZTS) reported Q4 2020 revenue of $1.8 billion, up 8% YoY, with net income of $359 million ($0.75/share). Adjusted net income was $438 million, relatively unchanged. Full-year revenue reached $6.7 billion, a 7% increase, with net income of $1.6 billion ($3.42/share). The company anticipates 2021 revenue growth of 9% to 11%, driven by strong performance in petcare and international markets. Key product approvals include Librela and Solensia for pain management in pets. Overall, Zoetis demonstrated resilience amidst COVID-19 challenges.
Summary not available.
Zoetis Inc (NYSE:ZTS) will host a webcast and conference call on Feb. 16, 2021, at 8:30 a.m. ET to discuss its fourth quarter and full year 2020 financial results. CEO Kristin Peck and CFO Glenn David will present the information and answer questions from analysts. A live webcast will be accessible on the Zoetis investor website, and a replay will be available following the call. The company is a leader in animal health, offering medicines, vaccines, and diagnostics in over 100 countries, generating $6.3 billion in revenue in 2019.
Zoetis (NYSE:ZTS) will participate in the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021. CEO Kristin Peck is scheduled to present at 10:00 a.m. ET and answer analysts' questions. Investors can access a live audio webcast of the presentation via investor.zoetis.com. A replay will be available post-event. Zoetis is a leader in animal health, with over 65 years of experience, offering medicines, vaccines, and diagnostics in over 100 countries, generating $6.3 billion in revenue in 2019.